Initiatives for family pharmacists and pharmacies

「Although the company promoted efforts to establish pharmacist and pharmacy services chosen by local residents, the number of prescriptions declined due to the closure of pharmacies as part of a review of the store network, resulting in difficult conditions.」

「当事業部門につきましては、地域の皆様から選ばれる「かかりつけ薬剤師・薬局」への取り組みを推進したものの、店舗網の見直しなどに伴う閉局の影響により処方箋枚数が減少し厳しい状況となりました。」

「Sales increased as prescription revenue per prescription grew following efforts to establish pharmacist and pharmacy services chosen by local residents, but operating profit declined due to higher personnel expenses and other factors. As a result, sales were ¥9,898 million, up 2.2% year on year, while the operating loss was ¥89 million, compared with operating profit of ¥106 million in the same period of the previous year.」

「Although the number of prescriptions increased as a result of the expanded store network from new openings in the previous fiscal year and efforts to establish pharmacist and pharmacy services chosen by local residents, operating profit declined due to higher personnel expenses and other factors.」

「In this business segment, as restraint in seeking medical care eased following the reclassification of COVID-19 to Category 5, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained strong. As a result, revenue was ¥19,358 million, up 6.8% year on year, and operating profit was ¥378 million, up 233.5% year on year, due in part to fewer new store openings than in the previous fiscal year and a decrease in the one-time costs associated with store openings.」

「In this business segment, as restraint in seeking medical care eased following the reclassification of COVID-19 to Category 5, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained strong. As a result, revenue was ¥14,385 million, up 7.0% year on year, and operating profit was ¥286 million, up 349.1% year on year, due in part to fewer new store openings than in the same period of the previous year and a decrease in the one-time costs associated with store openings.」

「As restraint in seeking medical care eased following the reclassification of COVID-19 to Category 5, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained strong. As a result, revenue was ¥9,467 million, up 7.5% year on year, and operating profit was ¥185 million, up 1,663.4% year on year, due in part to fewer new store openings than in the same period of the previous year and a decrease in the one-time costs associated with store openings.」

「In this business segment, the number of prescriptions handled increased and performance remained solid due to the effects of expanding the store network through new store openings and initiatives for “family pharmacists and pharmacies” chosen by local residents.」

「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were somewhat difficult due to higher SG&A expenses associated with new store openings.」

「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were somewhat difficult due to higher SG&A expenses associated with new store openings. As a result, revenue was ¥8,805 million, up 0.9% year on year, and operating profit was ¥10 million, down 77.5% year on year.」

「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were difficult due to the absence of sales of large medical equipment recorded in the same period of the previous year, the effects of revisions to dispensing fees and drug prices, and higher SG&A expenses associated with new store openings. As a result, revenue was ¥4,321 million, down 0.6% year on year, and the operating loss was ¥67 million, compared with an operating loss of ¥11 million in the same period of the previous year.」

「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained solid. As a result, revenue was ¥13,260 million, up 3.0% year on year, and operating profit was ¥83 million, compared with an operating loss of ¥48 million in the same period of the previous year.」

「In this business segment, the number of prescriptions increased due to the benefits of expanding the store network through new openings and initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors, and performance remained solid. As a result, revenue was ¥8,723 million, up 3.2% year on year, and operating profit was ¥46 million, compared with an operating loss of ¥98 million in the same period of the previous year.」

「In this business segment, the number of prescriptions increased as a result of initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, among other factors. However, conditions were somewhat difficult due to continued restraint in seeking medical care and higher SG&A expenses associated with new store openings. As a result, revenue was ¥4,348 million, up 3.6% year on year, and the operating loss was ¥11 million, compared with an operating loss of ¥117 million in the same period of the previous year.」

「In this business segment, although we promoted initiatives to become the “primary-care pharmacist and pharmacy” chosen by local residents, the number of visitors declined as people refrained from seeking medical care, resulting in difficult conditions. As a result, revenue was ¥17,260 million, down 3.5% year on year, and the operating loss was ¥2 million, compared with operating profit of ¥74 million in the previous fiscal year.」

「Although the company promoted initiatives to provide a family pharmacist and pharmacy chosen by local residents, performance remained weak as the number of pharmacy visits declined because patients refrained from visiting medical institutions. As a result, net sales were ¥1,287.6 million, down 3.7% year on year, and the company recorded an operating loss of ¥4.8 million, compared with operating profit of ¥0 million in the previous fiscal year.」

「Although the company promoted initiatives to provide a family pharmacist and pharmacy chosen by local residents, performance remained weak as the number of pharmacy visits declined because patients refrained from visiting medical institutions. As a result, net sales were ¥845.1 million, down 4.3% year on year, and the company recorded an operating loss of ¥9.8 million, compared with an operating loss of ¥2.6 million in the previous fiscal year.」

「Although the Company promoted initiatives for “family pharmacists and pharmacies” chosen by local residents, the number of visitors declined due to reduced visits to medical institutions, and performance remained weak.」

「The number of prescriptions processed grew as a result of new store openings and strengthened initiatives to provide a family pharmacist and pharmacy chosen by local residents. However, selling, general and administrative expenses increased in association with new store openings. As a result, net sales were ¥1,336.6 million, up 5.0% year on year, and operating profit was ¥0 million, compared with an operating loss of ¥33.1 million in the previous fiscal year.」

「In this business segment, the number of prescriptions handled increased due to the effects of expanding the store network through new store openings and initiatives for “family pharmacists and pharmacies” chosen by local residents.」

「Although the number of prescriptions handled increased due to the effects of expanding the store network through new openings and initiatives to develop family pharmacist and pharmacy services chosen by local residents, conditions were somewhat challenging as the impact of the previous year's revisions to dispensing fees and drug prices continued.」

「In this business segment, the number of prescriptions handled increased due to the effects of expanding the store network through new store openings and M&A and stronger initiatives in home healthcare. However, conditions remained challenging due to the impact of revisions to dispensing fees and drug prices and increased selling, general and administrative expenses associated with new store openings.」

「This segment performed well as the number of prescriptions handled increased due to the effects of expanding the store network through new openings and M&A, while initiatives in home healthcare and the development of family pharmacist and pharmacy services were also advanced.」

「This segment performed well as the number of prescriptions handled increased due to the effects of expanding the store network through new openings and M&A, while initiatives in home healthcare and the development of family pharmacist and pharmacy services were also advanced.」